Literature DB >> 16619289

Roles for phosphoinositide 3-kinases, Bruton's tyrosine kinase, and Jun kinases in B lymphocyte chemotaxis and homing.

Saida Ortolano1, Il-Young Hwang, Sang-Bae Han, John H Kehrl.   

Abstract

B lymphocyte chemokine receptors signal to downstream effectors by activating heterotrimeric G proteins. However, many of these effectors remain unknown and the known ones often have ill-defined roles in B cell trafficking. Here we report that pharmacological inhibitors of phosphoinositide 3-kinases (wortmannin, WMN), Bruton's tyrosine kinase (LFM-A13), and Jun kinases (SP600125) all significantly impair CXCL12-induced mouse B cell chemotaxis and that of a human B lymphoma cell line. Examination of two CXCR4-induced signaling pathways revealed that LFM-A13 and WMN blocked Akt activation, while SP600125 and WMN blocked JNK activation. Each of the inhibitors impaired the homing of transferred B cells to peripheral lymph nodes. Intravital imaging of control and inhibitor-treated mouse B cells in the inguinal lymph node high endothelial venules (HEV) demonstrated a 17%, 35%, and 60% reduction in the number of firmly adherent B cells with LFM-A13, SP600125, and WMN, respectively. These results implicate chemokine receptor mediated activation of phosphoinositide 3-kinases in the firm adhesion of mouse B cells within peripheral lymph node HEV, while Bruton's tyrosine kinase and JNK activation are less important and more likely needed during B cell transmigration through the endothelium and/or trafficking into the lymph node parenchyma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16619289     DOI: 10.1002/eji.200535799

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  21 in total

Review 1.  B cell receptor signaling in chronic lymphocytic leukemia.

Authors:  Jan A Burger; Nicholas Chiorazzi
Journal:  Trends Immunol       Date:  2013-08-05       Impact factor: 16.687

Review 2.  Chemoattractant receptor signaling and the control of lymphocyte migration.

Authors:  John H Kehrl
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 3.  Bruton's tyrosine kinase (BTK) inhibitors in clinical trials.

Authors:  Jan A Burger
Journal:  Curr Hematol Malig Rep       Date:  2014-03       Impact factor: 3.952

4.  The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.

Authors:  Sabine Ponader; Shih-Shih Chen; Joseph J Buggy; Kumudha Balakrishnan; Varsha Gandhi; William G Wierda; Michael J Keating; Susan O'Brien; Nicholas Chiorazzi; Jan A Burger
Journal:  Blood       Date:  2011-12-16       Impact factor: 22.113

Review 5.  Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia.

Authors:  Jan A Burger
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

Review 6.  Secondary mutations as mediators of resistance to targeted therapy in leukemia.

Authors:  Naval Daver; Jorge Cortes; Farhad Ravandi; Keyur P Patel; Jan A Burger; Marina Konopleva; Hagop Kantarjian
Journal:  Blood       Date:  2015-03-20       Impact factor: 22.113

7.  Bruton's tyrosine kinase is a potential therapeutic target in prostate cancer.

Authors:  Leila Kokabee; Xianhui Wang; Christopher J Sevinsky; Wei Lin Winnie Wang; Lindsay Cheu; Sridar V Chittur; Morteza Karimipoor; Martin Tenniswood; Douglas S Conklin
Journal:  Cancer Biol Ther       Date:  2015-09-18       Impact factor: 4.742

8.  Gαi2 and Gαi3 Differentially Regulate Arrest from Flow and Chemotaxis in Mouse Neutrophils.

Authors:  Yoshihiro Kuwano; Micha Adler; Hong Zhang; Alex Groisman; Klaus Ley
Journal:  J Immunol       Date:  2016-03-14       Impact factor: 5.422

9.  Differential role of reactive oxygen species in the activation of mitogen-activated protein kinases and Akt by key receptors on B-lymphocytes: CD40, the B cell antigen receptor, and CXCR4.

Authors:  Rosaline L Lee; Jens Westendorf; Michael R Gold
Journal:  J Cell Commun Signal       Date:  2007-05-10       Impact factor: 5.782

Review 10.  Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling.

Authors:  Jan A Burger; Emili Montserrat
Journal:  Blood       Date:  2012-12-20       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.